Skip to main content
Erschienen in: Annals of Hematology 9/2023

02.06.2023 | Original Article

Risk factors and prognosis of early death in secondary hemophagocytic lymphohistiocytosis

verfasst von: Qiaolei Zhang, Lixia Zhu, De Zhou, Li Li, Wanzhuo Xie, Yamin Tan, Xiujin Ye

Erschienen in: Annals of Hematology | Ausgabe 9/2023

Einloggen, um Zugang zu erhalten

Abstract

The aim of our study was to summarize the clinical characteristics of early death patients with newly diagnosed secondary hemophagocytic lymphohistiocytosis (sHLH), analyze the risk factors of early death, and analyze the survival of patients. The clinical characteristics of 324 newly diagnosed sHLH patients admitted to the First Affiliated Hospital of Zhejiang University Medical College and Zhejiang Provincial Cancer Hospital from January 2014 to February 2021 were analyzed retrospectively. Analyze the independent risk factors of early death, compare the secondary diseases and treatment methods of patients with early death group and non early death group, and analyze the survival of all patients with sHLH. Among the 324 newly diagnosed patients with sHLH, 134 died early, with an early mortality rate of 41.4%. Comparing the clinical characteristics of patients with early death group and patients with non early death group, logistic regression model was used to conduct multifactor analysis. Age > 60 years, Plt ≤ 20.0 × 109/L, APTT > 36.0 s and LDH > 1000.0 U/L were independent risk factors for early death of newly diagnosed sHLH patients (P < 0.05). Comparing the secondary diseases and treatment methods between early death group and non early death group, the proportion of sHLH patients secondary to lymphoma was higher in early death group than that in non early death group (P < 0.05). The proportion of sHLH patients secondary to connective tissue disease and infection was lower in early death group than that in non early death group (P < 0.05), and the proportion of sHLH patients used hormone combined chemotherapy was lower in early death group than that in non early death group (P < 0.05). The median follow-up time of all patients was 12.0 (1–65) months. The 5-year OS rates of patients with age > 60 years and age ≤ 60 years were 25.8% and 49.6% respectively (P < 0.001); The 5-year OS rates of patients with Plt > 20.0 × 109/L and Plt ≤ 20.0 × 109/L were 52.5% and 25.5% respectively (P < 0.001); The 5-year OS rates of patients with APTT > 36.0 s and APTT ≤ 36.0 s were 34.5% and 57.4% respectively (P < 0.001); The 5-year OS rates of patients with LDH > 1000.0 U/L and LDH ≤ 1000.0 U/L were 23.3% and 56.3% respectively (P < 0.001). Age > 60 years, Plt ≤ 20.0 × 109/L, APTT > 36.0 s and LDH > 1000.0 U/L are independent risk factors for early death of sHLH patients. The early mortality of lymphoma associated HLH (LA-HLH) patients is high, and early use of hormone combined chemotherapy can reduce the early mortality.
Literatur
1.
Zurück zum Zitat La Rosée P, Horne A, Hines M, von Bahr GT, Machowicz R, Berliner N, Birndt S, Gil-Herrera J, Girschikofsky M, Jordan MB, Kumar A, van Laar JAM, Lachmann G, Nichols KE, Ramanan AV, Wang Y, Wang Z, Janka G, Henter JI (2019) Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood 133(23):2465–2477. https://doi.org/10.1182/blood.2018894618CrossRefPubMed La Rosée P, Horne A, Hines M, von Bahr GT, Machowicz R, Berliner N, Birndt S, Gil-Herrera J, Girschikofsky M, Jordan MB, Kumar A, van Laar JAM, Lachmann G, Nichols KE, Ramanan AV, Wang Y, Wang Z, Janka G, Henter JI (2019) Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood 133(23):2465–2477. https://​doi.​org/​10.​1182/​blood.​2018894618CrossRefPubMed
5.
Zurück zum Zitat Tang S, Zhao C, Chen W (2020) Aggressive diffuse large B-cell lymphoma with hemophagocytic lymphohistiocytosis: report of one case. Int J Clin Exp Pathol 13(9):2392–2396. eCollection2020PubMedPubMedCentral Tang S, Zhao C, Chen W (2020) Aggressive diffuse large B-cell lymphoma with hemophagocytic lymphohistiocytosis: report of one case. Int J Clin Exp Pathol 13(9):2392–2396. eCollection2020PubMedPubMedCentral
9.
Zurück zum Zitat Tamamyan GN, Kantarjian HM, Ning J, Jain P, Sasaki K, McClain KL, Allen CE, Pierce SA, Cortes JE, Ravandi F, Konopleva MY, Garcia-Manero G, Benton CB, Chihara D, Rytting ME, Wang S, Abdelall W, Konoplev SN, Daver NG (2016) Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes. Cancer 122(18):2857–2866. https://doi.org/10.1002/cncr.30084CrossRefPubMed Tamamyan GN, Kantarjian HM, Ning J, Jain P, Sasaki K, McClain KL, Allen CE, Pierce SA, Cortes JE, Ravandi F, Konopleva MY, Garcia-Manero G, Benton CB, Chihara D, Rytting ME, Wang S, Abdelall W, Konoplev SN, Daver NG (2016) Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes. Cancer 122(18):2857–2866. https://​doi.​org/​10.​1002/​cncr.​30084CrossRefPubMed
11.
Zurück zum Zitat Birndt S, Schenk T, Heinevetter B, Brunkhorst FM, Maschmeyer G, Rothmann F, Weber T, Müller M, Panse J, Penack O, Schroers R, Braess J, Frickhofen N, Ehl S, Janka G, Lehmberg K, Pletz MW, Hochhaus A, Ernst T, La Rosée P (2020) Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registry. J Cancer Res Clin Oncol 146(4):1065–1077. https://doi.org/10.1007/s00432-020-03139-4CrossRefPubMedPubMedCentral Birndt S, Schenk T, Heinevetter B, Brunkhorst FM, Maschmeyer G, Rothmann F, Weber T, Müller M, Panse J, Penack O, Schroers R, Braess J, Frickhofen N, Ehl S, Janka G, Lehmberg K, Pletz MW, Hochhaus A, Ernst T, La Rosée P (2020) Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registry. J Cancer Res Clin Oncol 146(4):1065–1077. https://​doi.​org/​10.​1007/​s00432-020-03139-4CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Bigenwald C, Fardet L, Coppo P, Meignin V, Lazure T, Fabiani B, Kohn M, Oksenhendler E, Boutboul D, Uzzan M, Lambotte O, Galicier L (2018) A comprehensive analysis of Lymphoma-associated haemophagocytic syndrome in a large French multicentre cohort detects some clues to improve prognosis. Br J Haematol 183(1):68–75. https://doi.org/10.1111/bjh.15506CrossRefPubMed Bigenwald C, Fardet L, Coppo P, Meignin V, Lazure T, Fabiani B, Kohn M, Oksenhendler E, Boutboul D, Uzzan M, Lambotte O, Galicier L (2018) A comprehensive analysis of Lymphoma-associated haemophagocytic syndrome in a large French multicentre cohort detects some clues to improve prognosis. Br J Haematol 183(1):68–75. https://​doi.​org/​10.​1111/​bjh.​15506CrossRefPubMed
25.
Zurück zum Zitat Paul T, Kalra M, Danewa A, Sachdeva P, Thatikonda KB, Sachdeva D, Sachdeva A (2022) Pediatric Hemophagocytic Lymphohistiocytosis - A Single Center Study. Indian Pediatr 59(4):283–286CrossRefPubMed Paul T, Kalra M, Danewa A, Sachdeva P, Thatikonda KB, Sachdeva D, Sachdeva A (2022) Pediatric Hemophagocytic Lymphohistiocytosis - A Single Center Study. Indian Pediatr 59(4):283–286CrossRefPubMed
28.
Zurück zum Zitat Tong HY, Ren YL, Liu H, Xiao F, Mai WY, Meng HT, Qian WB, Huang J, Mao LP, Tong Y, Wang L, Qian JJ, Jin J (2008) Clinical characteristics of T-cell lymphoma associated with hemophagocytic syndrome: comparison of T-cell lymphoma with and without hemophagocytic syndrome. Leuk Lymphoma 49(1):81–87. https://doi.org/10.1080/10428190701713630CrossRefPubMed Tong HY, Ren YL, Liu H, Xiao F, Mai WY, Meng HT, Qian WB, Huang J, Mao LP, Tong Y, Wang L, Qian JJ, Jin J (2008) Clinical characteristics of T-cell lymphoma associated with hemophagocytic syndrome: comparison of T-cell lymphoma with and without hemophagocytic syndrome. Leuk Lymphoma 49(1):81–87. https://​doi.​org/​10.​1080/​1042819070171363​0CrossRefPubMed
29.
Zurück zum Zitat Li F, Li P, Zhang R, Yang G, Ji D, Huang X, Xu Q, Wei Y, Rao J, Huang R, Chen G (2014) Identification of clinical features of lymphoma-associated hemophagocytic syndrome (LAHS): an analysis of 69 patients with hemophagocytic syndrome from a single-center in central region of China. Med Oncol 31:902. https://doi.org/10.1007/s12032-014-0902-yCrossRefPubMed Li F, Li P, Zhang R, Yang G, Ji D, Huang X, Xu Q, Wei Y, Rao J, Huang R, Chen G (2014) Identification of clinical features of lymphoma-associated hemophagocytic syndrome (LAHS): an analysis of 69 patients with hemophagocytic syndrome from a single-center in central region of China. Med Oncol 31:902. https://​doi.​org/​10.​1007/​s12032-014-0902-yCrossRefPubMed
32.
Zurück zum Zitat Zhou L, Liu Y, Wen Z, Yang S, Li M, Zhu Q, Qiu S, Gao Y, Wang H, Yuan Y, Zhang H, Chen C, Zeng W, Guan Z, Pan X (2020) Ruxolitinib combined with doxorubicin, etoposide, and dexamethasone for the treatment of the lymphoma-associated hemophagocytic syndrome. J Cancer Res Clin Oncol 146(11):3063–3074. https://doi.org/10.1007/s00432-020-03301-yCrossRefPubMed Zhou L, Liu Y, Wen Z, Yang S, Li M, Zhu Q, Qiu S, Gao Y, Wang H, Yuan Y, Zhang H, Chen C, Zeng W, Guan Z, Pan X (2020) Ruxolitinib combined with doxorubicin, etoposide, and dexamethasone for the treatment of the lymphoma-associated hemophagocytic syndrome. J Cancer Res Clin Oncol 146(11):3063–3074. https://​doi.​org/​10.​1007/​s00432-020-03301-yCrossRefPubMed
Metadaten
Titel
Risk factors and prognosis of early death in secondary hemophagocytic lymphohistiocytosis
verfasst von
Qiaolei Zhang
Lixia Zhu
De Zhou
Li Li
Wanzhuo Xie
Yamin Tan
Xiujin Ye
Publikationsdatum
02.06.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 9/2023
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-023-05153-1

Weitere Artikel der Ausgabe 9/2023

Annals of Hematology 9/2023 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.